Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer

PHASE1/PHASE2UnknownINTERVENTIONAL

Enrollment

380

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

October 7, 2024

Study Completion Date

October 7, 2025

Conditions

Advanced Non-Small-Cell Lung Cancer

Interventions

DRUG

HS-10376

HS-10376 will be administered orally once daily in a continuous regimen

Trial Locations (1)

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin